A Preview of the 2013 ASH Annual Meeting

December 5, 2013
Marcel R.M. van den Brink, MD, PhD

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.

Abstract 69

Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy

  • Research in this area has come to fruition in the last year in ALL
  • This genetically manipulated T cell therapy can be used in patients with ALL who have failed other therapies
  • This therapy could provide a ‘bridge’ to life-saving bone marrow transplant

Abstract 852

Combining Ibrutinib With R-CHOP: Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell NHL

  • Ibrutinib has been used in a variety of B-cell tumors
  • Results from this study are particularly promising because response rates were higher than what would be normally seen in this space

<<<

Back to the conference page